Free Trial
→ URGENT: Someone's Moving Gold Out of London... (From Golden Portfolio) (Ad) Buy SBTX Stock  Free SBTX Stock Alerts

Silverback Therapeutics (SBTX) Financials

Silverback Therapeutics logo
$14.46 +0.30 (+2.12%)
As of 05/2/2025
Compare
Annual Income Statements for Silverback Therapeutics

Annual Income Statements for Silverback Therapeutics

This table shows Silverback Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Net Income / (Loss) Attributable to Common Shareholders		 -33 -20 -35 -54 8.00
Consolidated Net Income / (Loss)		 -33 -20 -35 -54 8.00
Net Income / (Loss) Continuing Operations		 -33 -20 -35 -54 8.00
Total Pre-Tax Income 		-33 -20 -35 -54 8.29
Total Operating Income		 -33 -19 -36 -68 -3.08
Total Gross Profit		 0.00 5.51 1.32 0.03 88
Total Revenue		 0.00 5.51 1.32 0.03 89
Operating Revenue		 - 5.51 1.32 0.03 89
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.98
Operating Cost of Revenue		 - - - - 0.98
Total Operating Expenses		 33 25 37 68 91
Selling, General & Admin Expense		 8.34 4.69 18 47 72
Research & Development Expense		 25 20 18 20 20
Total Other Income / (Expense), net		 -0.03 -0.79 0.83 13 11
Other Income / (Expense), net		 - -0.79 0.97 13 11
Income Tax Expense		 - - - 0.00 0.29
Basic Earnings per Share		 ($11.33) ($0.70) ($0.87) ($0.57) $0.08
Weighted Average Basic Shares Outstanding		 2.91M 28.87M 39.96M 95.22M 96.94M
Diluted Earnings per Share		 ($11.33) ($0.70) ($0.87) ($0.57) $0.08
Weighted Average Diluted Shares Outstanding		 2.91M 28.87M 39.96M 95.22M 102.39M
Weighted Average Basic & Diluted Shares Outstanding		 2.91M 34.93M 94.40M 96.50M 98.12M

Quarterly Income Statements for Silverback Therapeutics

This table shows Silverback Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Period end date 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024
Net Income / (Loss) Attributable to Common Shareholders		 -6.58 -14 -15 -17 -15 -7.19 -10 -13 -19 49
Consolidated Net Income / (Loss)		 -6.58 -14 -15 -17 -15 -7.17 -10 -13 -19 50
Net Income / (Loss) Continuing Operations		 -6.58 -14 -15 -17 -15 -7.17 -10 -13 -19 50
Total Pre-Tax Income 		-6.58 -14 -15 -17 -15 -7.17 -10 -13 -19 50
Total Operating Income		 -6.63 -15 -19 -21 -18 -10 -13 -15 -22 47
Total Gross Profit		 0.19 - 0.02 0.01 0.00 - 0.00 0.50 2.07 86
Total Revenue		 0.19 - 0.02 0.01 0.00 - 0.00 0.50 2.07 87
Operating Revenue		 0.19 - 0.02 0.01 0.00 - 0.00 0.50 2.07 87
Total Cost of Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 0.98
Total Operating Expenses		 6.82 15 19 21 18 10 13 16 24 38
Selling, General & Admin Expense		 2.93 11 12 13 15 6.82 7.96 8.94 19 35
Research & Development Expense		 3.89 4.71 6.55 7.31 3.00 3.40 5.23 6.90 4.42 3.03
Total Other Income / (Expense), net		 0.05 1.01 3.75 3.23 3.11 3.06 2.90 2.82 2.62 3.03
Other Income / (Expense), net		 0.05 1.15 3.75 3.23 3.11 3.06 2.90 2.82 2.62 3.03
Basic Earnings per Share		 ($0.21) ($0.21) ($0.16) ($0.18) ($0.16) ($0.07) ($0.11) ($0.13) ($0.20) $0.52
Weighted Average Basic Shares Outstanding		 30.76M 39.96M 94.23M 94.91M 95.58M 95.22M 96.49M 96.83M 97.03M 96.94M
Diluted Earnings per Share		 ($0.21) ($0.21) ($0.16) ($0.18) ($0.16) ($0.07) ($0.11) ($0.13) ($0.20) $0.52
Weighted Average Diluted Shares Outstanding		 30.76M 39.96M 94.23M 94.91M 95.58M 95.22M 96.49M 96.83M 97.03M 102.39M
Weighted Average Basic & Diluted Shares Outstanding		 36.06M 94.40M 94.77M 95.57M 96.00M 96.50M 96.90M 96.94M 97.19M 98.12M

Annual Cash Flow Statements for Silverback Therapeutics

This table details how cash moves in and out of Silverback Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Net Change in Cash & Equivalents		 376 36 150 -140 -20
Net Cash From Operating Activities		 -31 -18 -40 -59 14
Net Cash From Continuing Operating Activities		 -31 -18 -40 -59 14
Net Income / (Loss) Continuing Operations		 -33 -20 -35 -54 8.00
Consolidated Net Income / (Loss)		 -33 -20 -35 -54 8.00
Depreciation Expense		 0.64 0.21 0.03 0.07 0.08
Amortization Expense		 0.03 - 0.29 -6.85 -7.25
Non-Cash Adjustments To Reconcile Net Income		 3.71 2.83 7.04 9.24 15
Changes in Operating Assets and Liabilities, net		 -2.63 -0.36 -13 -7.36 -1.81
Net Cash From Investing Activities		 -0.92 -0.06 -0.20 -87 -106
Net Cash From Continuing Investing Activities		 -0.92 -0.06 -0.20 -87 -106
Purchase of Property, Plant & Equipment		 -0.92 -0.06 -0.20 -0.18 -0.56
Purchase of Investments		 0.00 0.00 0.00 -272 -356
Sale and/or Maturity of Investments		 - - 0.00 185 258
Other Investing Activities, net		 - - - 0.00 -7.50
Net Cash From Financing Activities		 409 53 191 6.90 72
Net Cash From Continuing Financing Activities		 409 53 191 6.90 72
Repayment of Debt		 -0.70 -1.82 -8.68 0.00 0.00
Issuance of Preferred Equity		 153 55 0.00 0.00 0.00
Issuance of Common Equity		 258 0.17 0.57 6.90 3.02
Other Financing Activities, net		 -2.61 0.00 199 0.00 69
Cash Interest Paid		 - 0.58 0.37 0.00 0.00

Quarterly Cash Flow Statements for Silverback Therapeutics

This table details how cash moves in and out of Silverback Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Period end date 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024
Net Change in Cash & Equivalents		 -7.27 173 -123 31 -58 10 -15 -19 3.03 11
Net Cash From Operating Activities		 -5.68 -20 -12 -17 -13 -17 -6.71 -7.28 -14 42
Net Cash From Continuing Operating Activities		 -5.68 -20 -12 -17 -13 -17 -6.71 -7.28 -14 42
Net Income / (Loss) Continuing Operations		 -6.58 -14 -15 -17 -15 -7.17 -10 -13 -19 50
Consolidated Net Income / (Loss)		 -6.58 -14 -15 -17 -15 -7.17 -10 -13 -19 50
Depreciation Expense		 0.01 0.01 0.02 0.02 0.02 0.01 0.01 0.02 0.02 0.03
Amortization Expense		 - 0.29 -1.81 -1.75 -1.56 -1.73 -1.98 -1.90 -1.83 -1.54
Non-Cash Adjustments To Reconcile Net Income		 0.50 5.84 2.25 2.10 2.61 2.28 3.35 3.37 3.59 4.23
Changes in Operating Assets and Liabilities, net		 0.39 -12 2.07 0.33 1.03 -11 2.21 3.76 2.88 -11
Net Cash From Investing Activities		 -0.03 -0.13 -112 45 -47 26 -8.51 -13 17 -102
Net Cash From Continuing Investing Activities		 -0.03 -0.13 -112 45 -47 26 -8.51 -13 17 -102
Purchase of Property, Plant & Equipment		 -0.03 -0.13 -0.19 -0.03 -0.04 0.09 -0.08 -0.04 -0.14 -0.30
Purchase of Investments		 - - -131 - -107 -34 -63 -88 -42 -163
Sale and/or Maturity of Investments		 - - 20 45 60 60 55 75 61 67
Other Investing Activities, net		 - - - - - - - - - -5.00
Net Cash From Financing Activities		 -1.56 194 1.32 2.85 0.92 1.81 0.26 0.55 0.68 71
Net Cash From Continuing Financing Activities		 -1.56 194 1.32 2.85 0.92 1.81 0.26 0.55 0.68 71
Issuance of Common Equity		 - 0.28 1.32 2.85 0.92 1.81 0.26 0.55 0.68 1.53

Annual Balance Sheets for Silverback Therapeutics

This table presents Silverback Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Total Assets		 395 61 281 233 351
Total Current Assets		 391 61 278 232 334
Cash & Equivalents		 387 60 211 71 51
Short-Term Investments		 - 0.00 64 157 263
Accounts Receivable		 - 0.00 - 0.00 8.18
Inventories, net		 - - - 0.00 5.21
Prepaid Expenses		 4.09 0.67 3.32 3.37 6.89
Plant, Property, & Equipment, net		 1.62 0.07 0.33 0.57 1.03
Total Noncurrent Assets		 2.53 0.64 3.41 0.89 16
Intangible Assets		 - - - 0.00 7.37
Other Noncurrent Operating Assets		 2.53 0.64 3.41 0.89 8.46
Total Liabilities & Shareholders' Equity		 395 61 281 233 351
Total Liabilities		 12 17 8.55 2.43 94
Total Current Liabilities		 9.60 8.19 5.44 2.39 23
Accounts Payable		 2.58 3.11 4.93 2.15 23
Other Current Liabilities		 0.90 0.14 0.23 0.24 0.60
Total Noncurrent Liabilities		 2.33 8.49 3.11 0.04 71
Other Noncurrent Operating Liabilities		 2.33 0.56 0.25 0.04 71
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 383 -31 273 231 257
Total Preferred & Common Equity		 383 -31 273 231 257
Preferred Stock		 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 383 -31 273 231 257
Common Stock		 480 11 349 362 380
Retained Earnings		 -97 -42 -77 -131 -123
Accumulated Other Comprehensive Income / (Loss)		 0.00 0.00 0.41 0.05 0.22

Quarterly Balance Sheets for Silverback Therapeutics

This table presents Silverback Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024
Period end date 9/30/2022 3/31/2023 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024
Total Assets		 271 271 259 249 228 222 218
Total Current Assets		 271 267 255 244 226 221 209
Cash & Equivalents		 203 88 119 61 56 37 40
Short-Term Investments		 63 177 133 181 168 182 165
Accounts Receivable		 - - - - - - 0.77
Inventories, net		 - - - - - - 0.72
Prepaid Expenses		 4.18 2.80 2.83 2.56 2.61 1.99 2.68
Plant, Property, & Equipment, net		 0.02 0.58 0.59 0.62 0.62 0.64 0.84
Total Noncurrent Assets		 0.25 3.26 3.12 3.47 0.73 0.59 7.97
Long-Term Investments		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Intangible Assets		 - - - - - - 7.50
Other Noncurrent Operating Assets		 0.25 3.26 3.12 3.47 0.73 0.59 0.47
Total Liabilities & Shareholders' Equity		 271 271 259 249 228 222 218
Total Liabilities		 3.99 10 10 11 3.72 6.73 17
Total Current Liabilities		 3.99 9.84 10 11 3.72 6.73 17
Short-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable		 0.13 9.60 9.82 11 3.50 6.57 17
Accrued Expenses		 3.65 0.00 0.00 0.00 0.00 0.00 0.00
Current Deferred Revenue		 - 0.01 0.00 0.00 0.00 0.00 0.00
Other Current Liabilities		 0.22 0.23 0.23 0.24 0.22 0.16 0.10
Total Noncurrent Liabilities		 0.00 0.20 0.15 0.09 0.00 0.00 0.00
Noncurrent Deferred Revenue		 - 0.00 0.00 0.00 0.00 0.00 0.00
Other Noncurrent Operating Liabilities		 0.00 0.20 0.15 0.09 0.00 0.00 0.00
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 267 261 249 237 224 215 201
Total Preferred & Common Equity		 267 261 249 237 224 215 201
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 267 261 249 237 224 215 201
Common Stock		 517 353 358 362 366 369 374
Retained Earnings		 -248 -92 -109 -124 -142 -154 -173
Accumulated Other Comprehensive Income / (Loss)		 -1.62 0.07 -0.18 -0.16 -0.12 -0.15 0.34

Annual Metrics and Ratios for Silverback Therapeutics

This table displays calculated financial ratios and metrics derived from Silverback Therapeutics' official financial filings.

Metric 2020 2021 2022 2023 2024
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Growth Metrics		 - - - - -
Revenue Growth		 0.00% 0.00% -76.10% -97.72% 297,063.33%
EBITDA Growth		 0.00% 37.89% -70.86% -78.65% 101.82%
EBIT Growth		 0.00% 38.50% -70.64% -57.39% 115.24%
NOPAT Growth		 0.00% 40.90% -82.56% -90.11% 93.70%
Net Income Growth		 0.00% 38.56% -71.33% -56.75% 114.71%
EPS Growth		 0.00% 93.82% -24.29% 34.48% 114.04%
Operating Cash Flow Growth		 0.00% 43.71% -128.22% -47.88% 122.86%
Free Cash Flow Firm Growth		 0.00% 0.00% -215.70% -69.12% 210.73%
Invested Capital Growth		 0.00% -141.71% 78.28% 260.54% -2,484.33%
Revenue Q/Q Growth		 0.00% 0.00% -80.71% 0.00% 3,371.53%
EBITDA Q/Q Growth		 0.00% 74.45% -230.69% 7.71% 101.97%
EBIT Q/Q Growth		 0.00% 74.43% -230.10% 11.58% 116.87%
NOPAT Q/Q Growth		 0.00% 75.43% -193.64% 7.17% 92.97%
Net Income Q/Q Growth		 0.00% 74.41% -235.89% 11.78% 116.29%
EPS Q/Q Growth		 0.00% -104.30% -264.15% 19.72% 115.69%
Operating Cash Flow Q/Q Growth		 0.00% 68.95% -582.11% 4.96% 129.54%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% -271.53% -11.58% 230.75%
Invested Capital Q/Q Growth		 0.00% 18.67% -432.22% 151.97% -1,469.50%
Profitability Metrics		 - - - - -
Gross Margin		 0.00% 100.00% 100.00% 100.00% 98.90%
EBITDA Margin		 0.00% -363.79% -2,600.53% -203,800.00% 1.25%
Operating Margin		 0.00% -353.32% -2,698.78% -225,066.67% -3.46%
EBIT Margin		 0.00% -367.65% -2,624.77% -181,216.67% 9.29%
Profit (Net Income) Margin		 0.00% -367.65% -2,635.41% -181,216.67% 8.97%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 96.52%
Interest Burden Percent		 100.09% 100.00% 100.41% 100.00% 100.00%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 3.48%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% -10,445.08% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% -10,442.26% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 10,423.49% 0.00%
Return on Equity (ROE)		 -8.61% -9.47% -21.84% -21.59% 3.28%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% -2,131.63% 0.00%
Operating Return on Assets (OROA)		 0.00% -8.87% -20.15% -21.13% 2.84%
Return on Assets (ROA)		 0.00% -8.87% -20.23% -21.13% 2.74%
Return on Common Equity (ROCE)		 -8.61% -7.78% -16.61% -21.59% 3.28%
Return on Equity Simple (ROE_SIMPLE)		 -8.61% 64.74% -12.71% -23.56% 3.11%
Net Operating Profit after Tax (NOPAT)		 -23 -14 -25 -47 -2.98
NOPAT Margin		 0.00% -247.33% -1,889.15% -157,546.67% -3.34%
Net Nonoperating Expense Percent (NNEP)		 -2.57% -3.03% -6.02% -2.82% 4.05%
Return On Investment Capital (ROIC_SIMPLE)		 - - - -20.48% -1.16%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 1.10%
SG&A Expenses to Revenue		 0.00% 85.13% 1,402.43% 157,613.33% 80.40%
R&D to Revenue		 0.00% 368.20% 1,396.35% 67,553.33% 21.96%
Operating Expenses to Revenue		 0.00% 453.32% 2,798.78% 225,166.67% 102.36%
Earnings before Interest and Taxes (EBIT)		 -33 -20 -35 -54 8.29
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -32 -20 -34 -61 1.11
Valuation Ratios		 - - - - -
Price to Book Value (P/BV)		 1.39 0.00 1.13 2.28 3.99
Price to Tangible Book Value (P/TBV)		 1.39 0.00 1.13 2.28 4.11
Price to Revenue (P/Rev)		 0.00 42.43 233.72 17,535.50 11.50
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 128.20
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.78%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 124.04 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 46.86 25.23 9,923.50 7.98
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 640.22
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 85.84
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 52.50
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 12.56
Leverage & Solvency		 - - - - -
Debt to Equity		 0.00 0.19 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.11 0.00 0.00 0.00
Financial Leverage		 -1.01 -1.02 -1.03 -1.00 -1.11
Leverage Ratio		 1.03 1.07 1.08 1.02 1.20
Compound Leverage Factor		 1.03 1.07 1.08 1.02 1.20
Debt to Total Capital		 0.22% 15.81% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.22% 6.54% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 9.27% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 142.99% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 99.78% -58.80% 100.00% 100.00% 100.00%
Debt to EBITDA		 -0.03 -0.42 0.00 0.00 0.00
Net Debt to EBITDA		 11.96 2.58 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 -0.25 0.00 0.00 0.00
Debt to NOPAT		 -0.04 -0.62 0.00 0.00 0.00
Net Debt to NOPAT		 16.74 3.79 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 -0.36 0.00 0.00 0.00
Altman Z-Score		 27.35 7.47 21.96 129.62 7.42
Noncontrolling Interest Sharing Ratio		 0.00% 17.78% 23.94% 0.00% 0.00%
Liquidity Ratios		 - - - - -
Current Ratio		 40.69 7.42 51.01 96.92 14.26
Quick Ratio		 40.26 7.34 50.40 95.51 13.75
Cash Flow Metrics		 - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -9.58 -30 -51 57
Operating Cash Flow to CapEx		 -3,401.96% -31,929.09% -20,139.70% -33,866.29% 2,406.39%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 -1,075.72 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 -1,107.34 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - -
Asset Turnover		 0.00 0.02 0.01 0.00 0.31
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 6.52 6.56 0.07 111.23
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.08
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 4,668.97
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 -4,668.97
Capital & Investment Metrics		 - - - - -
Invested Capital		 -2.85 -6.88 -1.50 2.40 -57
Invested Capital Turnover		 0.00 -1.13 -0.31 0.07 -3.25
Increase / (Decrease) in Invested Capital		 0.00 -4.04 5.39 3.90 -60
Enterprise Value (EV)		 147 258 33 298 711
Market Capitalization		 533 234 308 526 1,025
Book Value per Share		 $131.68 ($0.89) $7.57 $2.40 $2.65
Tangible Book Value per Share		 $131.68 ($0.89) $7.57 $2.40 $2.57
Total Capital		 384 53 273 231 257
Total Debt		 0.84 8.41 0.00 0.00 0.00
Total Long-Term Debt		 0.00 4.93 0.00 0.00 0.00
Net Debt		 -386 -52 -274 -228 -314
Capital Expenditures (CapEx)		 0.92 0.06 0.20 0.18 0.56
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -4.67 -4.04 -2.13 0.98 -3.17
Debt-free Net Working Capital (DFNWC)		 382 56 272 229 311
Net Working Capital (NWC)		 381 53 272 229 311
Net Nonoperating Expense (NNE)		 9.90 6.63 9.82 7.10 -11
Net Nonoperating Obligations (NNO)		 -386 -52 -274 -228 -314
Total Depreciation and Amortization (D&A)		 0.67 0.21 0.32 -6.78 -7.18
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% -73.39% -161.47% 3,250.00% -3.55%
Debt-free Net Working Capital to Revenue		 0.00% 1,017.47% 20,688.15% 764,450.00% 348.69%
Net Working Capital to Revenue		 0.00% 954.29% 20,688.15% 764,450.00% 348.69%
Earnings Adjustments		 - - - - -
Adjusted Basic Earnings per Share		 $0.00 ($2.56) ($0.87) ($0.57) $0.08
Adjusted Weighted Average Basic Shares Outstanding		 0.00 35.14M 39.96M 95.22M 96.94M
Adjusted Diluted Earnings per Share		 $0.00 ($2.56) ($0.87) ($0.57) $0.08
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 35.14M 39.96M 95.22M 102.39M
Adjusted Basic & Diluted Earnings per Share		 $0.00 ($2.56) $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 34.93M 94.40M 96.50M 98.12M
Normalized Net Operating Profit after Tax (NOPAT)		 -23 -14 -25 -47 -2.98
Normalized NOPAT Margin		 0.00% -247.33% -1,889.15% -157,546.67% -3.34%
Pre Tax Income Margin		 0.00% -367.65% -2,635.41% -181,216.67% 9.29%
Debt Service Ratios		 - - - - -
EBIT to Interest Expense		 -1,135.10 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 -794.57 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 -1,166.72 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 -826.19 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics and Ratios for Silverback Therapeutics

This table displays calculated financial ratios and metrics derived from Silverback Therapeutics' official financial filings.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Period end date 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024
Growth Metrics		 - - - - - - - - - -
Revenue Growth		 0.00% 0.00% -96.98% -97.84% -100.00% 0.00% -100.00% 4,900.00% 0.00% 0.00%
EBITDA Growth		 70.74% -130.26% -132.64% -195.83% -149.47% 36.50% 26.80% 24.60% -27.60% 648.32%
EBIT Growth		 70.98% -130.65% -106.36% -170.56% -125.82% 49.84% 31.21% 27.94% -28.67% 800.64%
NOPAT Growth		 70.77% -123.19% -163.60% -224.76% -171.16% 33.78% 29.50% 25.54% -20.97% 759.34%
Net Income Growth		 70.94% -131.52% -106.36% -170.56% -125.82% 50.32% 31.21% 27.94% -28.67% 796.62%
EPS Growth		 67.69% -117.65% 33.33% 14.29% 23.81% 66.67% 31.25% 27.78% -25.00% 842.86%
Operating Cash Flow Growth		 70.28% -173.48% -79.48% -139.02% -124.62% 15.09% 46.01% 56.33% -13.35% 341.33%
Free Cash Flow Firm Growth		 -82.86% -131.98% -158.02% -27.90% 44.55% 31.77% 10.01% 23.13% -115.46% 1,066.43%
Invested Capital Growth		 105.32% 78.28% 26.06% -7.47% -1,126.22% 260.54% 106.95% 4.18% 21.05% -2,484.33%
Revenue Q/Q Growth		 -59.27% 0.00% 0.00% -50.00% -100.00% 0.00% 0.00% 0.00% 313.60% 4,086.70%
EBITDA Q/Q Growth		 -1.84% -112.74% -19.73% -14.04% 14.12% 45.85% -37.56% -17.46% -45.35% 332.68%
EBIT Q/Q Growth		 -2.54% -117.06% -4.70% -16.10% 14.42% 51.78% -43.58% -21.61% -52.83% 362.56%
NOPAT Q/Q Growth		 -4.51% -132.93% -21.17% -10.10% 12.74% 43.12% -29.00% -16.28% -41.77% 410.03%
Net Income Q/Q Growth		 -2.54% -119.19% -3.69% -16.10% 14.42% 51.78% -43.58% -21.61% -52.83% 361.05%
EPS Q/Q Growth		 0.00% 0.00% 23.81% -12.50% 11.11% 56.25% -57.14% -18.18% -53.85% 360.00%
Operating Cash Flow Q/Q Growth		 18.53% -260.74% 39.36% -34.11% 23.43% -36.37% 61.45% -8.48% -98.75% 390.34%
Free Cash Flow Firm Q/Q Growth		 -22.36% -19.51% 11.75% 0.89% 46.95% -47.05% -16.39% 15.34% -48.71% 759.57%
Invested Capital Q/Q Growth		 113.23% -432.22% -127.02% -7.72% -26.31% 151.97% -90.17% -1,584.32% -4.08% -1,469.50%
Profitability Metrics		 - - - - - - - - - -
Gross Margin		 100.00% 0.00% 100.00% 100.00% 0.00% 0.00% 0.00% 100.00% 100.00% 98.87%
EBITDA Margin		 -3,479.37% 0.00% -83,750.00% -191,020.00% 0.00% 0.00% 0.00% -2,880.40% -1,012.23% 56.26%
Operating Margin		 -3,507.94% 0.00% -93,565.00% -206,030.00% 0.00% 0.00% 0.00% -3,068.00% -1,051.64% 54.51%
EBIT Margin		 -3,483.07% 0.00% -74,805.00% -173,700.00% 0.00% 0.00% 0.00% -2,503.20% -924.95% 58.01%
Profit (Net Income) Margin		 -3,483.07% 0.00% -74,805.00% -173,700.00% 0.00% 0.00% 0.00% -2,503.20% -924.95% 57.67%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 99.43%
Interest Burden Percent		 100.00% 100.98% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 8.52% -21.84% -15.29% -20.23% -24.44% 0.00% -20.49% -19.34% -22.41% 3.28%
Cash Return on Invested Capital (CROIC)		 3,919.11% 0.00% 0.00% 0.00% 0.00% -2,131.63% -19,927.67% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 -76.20% 0.00% -172.51% -137.64% 0.00% 0.00% 0.00% -5.21% -10.19% 17.70%
Return on Assets (ROA)		 -76.20% 0.00% -172.51% -137.64% 0.00% 0.00% 0.00% -5.21% -10.19% 17.60%
Return on Common Equity (ROCE)		 8.52% -16.61% -15.29% -20.23% -24.44% 0.00% -20.49% -19.34% -22.41% 3.28%
Return on Equity Simple (ROE_SIMPLE)		 9.56% 0.00% -16.23% -21.46% -25.97% 0.00% -22.20% -20.83% -24.43% 0.00%
Net Operating Profit after Tax (NOPAT)		 -4.64 -11 -13 -14 -13 -7.16 -9.23 -11 -15 47
NOPAT Margin		 -2,455.56% 0.00% -65,495.50% -144,221.00% 0.00% 0.00% 0.00% -2,147.60% -736.15% 54.51%
Net Nonoperating Expense Percent (NNEP)		 -0.64% -2.22% -0.66% -1.10% -0.90% 0.00% -0.43% -0.76% -1.75% 1.01%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - -3.10% - - - 18.38%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 1.13%
SG&A Expenses to Revenue		 1,548.15% 0.00% 60,905.00% 133,050.00% 0.00% 0.00% 0.00% 1,788.80% 932.35% 40.99%
R&D to Revenue		 2,059.79% 0.00% 32,760.00% 73,080.00% 0.00% 0.00% 0.00% 1,379.20% 213.88% 3.50%
Operating Expenses to Revenue		 3,607.94% 0.00% 93,665.00% 206,130.00% 0.00% 0.00% 0.00% 3,168.00% 1,151.64% 44.36%
Earnings before Interest and Taxes (EBIT)		 -6.58 -14 -15 -17 -15 -7.17 -10 -13 -19 50
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -6.58 -14 -17 -19 -16 -8.88 -12 -14 -21 49
Valuation Ratios		 - - - - - - - - - -
Price to Book Value (P/BV)		 0.70 1.13 2.35 2.55 1.52 2.28 4.41 3.83 6.99 3.99
Price to Tangible Book Value (P/TBV)		 0.70 1.13 2.35 2.55 1.52 2.28 4.41 3.83 7.27 4.11
Price to Revenue (P/Rev)		 27.46 233.72 913.17 2,899.49 12,041.61 17,535.50 98,624.59 1,649.16 547.37 11.50
Price to Earnings (P/E)		 4.22 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 128.20
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 23.71% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.78%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 124.04 3,231.41 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 25.23 520.08 1,747.85 3,978.21 9,923.50 76,261.39 1,211.67 467.69 7.98
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 640.22
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 85.84
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 52.50
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 12.56
Leverage & Solvency		 - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -1.01 -1.03 -1.01 -1.01 -1.01 -1.00 -1.01 -1.02 -1.02 -1.11
Leverage Ratio		 1.04 1.08 1.05 1.05 1.03 1.02 1.03 1.04 1.06 1.20
Compound Leverage Factor		 1.04 1.09 1.05 1.05 1.03 1.02 1.03 1.04 1.06 1.20
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 28.01 22.20 37.22 37.68 19.46 130.29 159.44 73.57 50.40 7.82
Noncontrolling Interest Sharing Ratio		 0.00% 23.94% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - -
Current Ratio		 67.87 51.01 27.18 25.37 21.87 96.92 60.90 32.82 12.56 14.26
Quick Ratio		 66.82 50.40 26.89 25.09 21.64 95.51 60.20 32.53 12.36 13.75
Cash Flow Metrics		 - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -14 -16 -14 -14 -7.52 -11 -13 -11 -16 107
Operating Cash Flow to CapEx		 -18,940.00% -16,267.46% -6,439.90% -55,563.33% -29,681.40% 0.00% -8,084.34% -19,155.26% -10,333.57% 13,908.61%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - -
Asset Turnover		 0.02 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.31
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 7.10 6.56 0.45 0.14 0.09 0.07 0.02 0.81 3.52 111.23
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.08
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 4,668.97
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -4,668.97
Capital & Investment Metrics		 - - - - - - - - - -
Invested Capital		 0.45 -1.50 -3.39 -3.66 -4.62 2.40 0.24 -3.50 -3.65 -57
Invested Capital Turnover		 -1.70 -0.31 -0.17 -0.06 -0.01 0.07 -0.01 -0.14 -0.62 -3.25
Increase / (Decrease) in Invested Capital		 8.91 5.39 1.20 -0.25 -5.07 3.90 3.63 0.15 0.97 -60
Enterprise Value (EV)		 -79 33 350 383 119 298 763 606 1,201 711
Market Capitalization		 187 308 615 635 361 526 986 825 1,406 1,025
Book Value per Share		 $7.53 $7.57 $2.77 $2.62 $2.48 $2.40 $2.32 $2.22 $2.07 $2.65
Tangible Book Value per Share		 $7.53 $7.57 $2.77 $2.62 $2.48 $2.40 $2.32 $2.22 $2.00 $2.57
Total Capital		 267 273 261 249 237 231 224 215 201 257
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -267 -274 -265 -252 -242 -228 -224 -219 -205 -314
Capital Expenditures (CapEx)		 0.03 0.13 0.19 0.03 0.04 -0.09 0.08 0.04 0.14 0.30
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 0.19 -2.13 -7.04 -7.23 -8.62 0.98 -1.11 -4.73 -12 -3.17
Debt-free Net Working Capital (DFNWC)		 267 272 258 245 233 229 223 214 192 311
Net Working Capital (NWC)		 267 272 258 245 233 229 223 214 192 311
Net Nonoperating Expense (NNE)		 1.94 3.62 1.86 2.95 2.28 0.01 1.06 1.78 3.90 -2.74
Net Nonoperating Obligations (NNO)		 -267 -274 -265 -252 -242 -228 -224 -219 -205 -314
Total Depreciation and Amortization (D&A)		 0.01 0.30 -1.79 -1.73 -1.54 -1.72 -1.97 -1.89 -1.81 -1.52
Debt-free, Cash-free Net Working Capital to Revenue		 2.71% -161.47% -1,045.62% -3,300.46% -28,720.00% 3,250.00% -11,060.00% -946.20% -485.12% -3.55%
Debt-free Net Working Capital to Revenue		 3,911.01% 20,688.15% 38,263.30% 111,863.01% 777,620.00% 764,450.00% 2,225,260.00% 42,802.60% 7,483.10% 348.69%
Net Working Capital to Revenue		 3,911.01% 20,688.15% 38,263.30% 111,863.01% 777,620.00% 764,450.00% 2,225,260.00% 42,802.60% 7,483.10% 348.69%
Earnings Adjustments		 - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.50) ($0.21) ($0.16) ($0.18) ($0.16) ($0.07) ($0.11) ($0.13) ($0.20) $0.52
Adjusted Weighted Average Basic Shares Outstanding		 35.46M 39.96M 94.23M 94.91M 95.58M 95.22M 96.49M 96.83M 97.03M 96.94M
Adjusted Diluted Earnings per Share		 ($0.50) ($0.21) ($0.16) ($0.18) ($0.16) ($0.07) ($0.11) ($0.13) ($0.20) $0.52
Adjusted Weighted Average Diluted Shares Outstanding		 35.46M 39.96M 94.23M 94.91M 95.58M 95.22M 96.49M 96.83M 97.03M 102.39M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 36.06M 94.40M 94.77M 95.57M 96.00M 96.50M 96.90M 96.94M 97.19M 98.12M
Normalized Net Operating Profit after Tax (NOPAT)		 -4.64 -11 -13 -14 -13 -7.16 -9.23 -11 -15 33
Normalized NOPAT Margin		 -2,455.56% 0.00% -65,495.50% -144,221.00% 0.00% 0.00% 0.00% -2,147.60% -736.15% 38.16%
Pre Tax Income Margin		 -3,483.07% 0.00% -74,805.00% -173,700.00% 0.00% 0.00% 0.00% -2,503.20% -924.95% 58.01%
Debt Service Ratios		 - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Frequently Asked Questions About Silverback Therapeutics' Financials

When does Silverback Therapeutics's financial year end?

According to the most recent income statement we have on file, Silverback Therapeutics' fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has Silverback Therapeutics' net income changed over the last 4 years?

Silverback Therapeutics' net income appears to be on a downward trend, with a most recent value of $8.00 million in 2024, falling from -$32.95 million in 2020. The previous period was -$54.37 million in 2023.

What is Silverback Therapeutics's operating income?
Silverback Therapeutics's total operating income in 2024 was -$3.08 million, based on the following breakdown:
  • Total Gross Profit: $88.17 million
  • Total Operating Expenses: $91.26 million
How has Silverback Therapeutics revenue changed over the last 4 years?

Over the last 4 years, Silverback Therapeutics' total revenue changed from $0.00 in 2020 to $89.15 million in 2024, a change of 8,914,900,000.0%.

How much debt does Silverback Therapeutics have?

Silverback Therapeutics' total liabilities were at $94.36 million at the end of 2024, a 3,786.1% increase from 2023, and a 691.1% increase since 2020.

How much cash does Silverback Therapeutics have?

In the past 4 years, Silverback Therapeutics' cash and equivalents has ranged from $50.82 million in 2024 to $386.57 million in 2020, and is currently $50.82 million as of their latest financial filing in 2024.

How has Silverback Therapeutics' book value per share changed over the last 4 years?

Over the last 4 years, Silverback Therapeutics' book value per share changed from 131.68 in 2020 to 2.65 in 2024, a change of -98.0%.


Related Companies

This page (NASDAQ:SBTX) was last updated on 5/5/2025 by MarketBeat.com Staff
From Our Partners
Warning: “DOGE Collapse” imminent
Elon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...
Altimetry | Sponsored
Shocking AI play that’s beats Nvidia by a country mile
You’ve seen the headlines about Nvidia. Now Tim Sykes is sounding the alarm — because what CEO Jensen Huang is...
Timothy Sykes | Sponsored
Elon Set to Shock the World on June 1st?
Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...
Brownstone Research | Sponsored
Gold Alert: The Truth About Fort Knox Is Coming
Owning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...
Golden Portfolio | Sponsored
Trump’s treachery
Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...
Porter & Company | Sponsored
Altucher: Turn $900 into $108,000 in just 12 months?
We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.
Paradigm Press | Sponsored
U.S. Stock Market Now on Verge of Collapse
The last time the U.S. economy looked like this, stocks didn't move for 16 years... And many investors lost...
Stansberry Research | Sponsored
How to invest in Elon Musk’s Optimus before its launch
Elon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...
InvestorPlace | Sponsored